SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (2562)4/28/1999 7:15:00 PM
From: Art Vandelay AIA  Read Replies (1) of 10280
 
I don't believe that it is an extension deal. Waxman Hatch just precluded ANDA applications which is what a generic app is. So to summarize. SEPR can file on Zyrtec in 2002 while the generics are out until 2007.

However, I don't believe this is true regarding Meridia. I think both SEPR and the generic can launch in 2002. That may be why SEPR intends to develop this themselves.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News